Leerink analyst Faisal A. Khurshid initiated coverage of Shattuck Labs (STTK) with an Outperform rating and $4 price target The firm views Shattuck Labs’ pivot into inflammatory bowel disease as an underappreciated opportunity, with lead program SL-325 representing a first-in-class approach with potential to improve upon related, clinically validated, TL1A targeting programs. The company expects key Phase 1 milestones for SL-325 over the next 1 year, and Leerink is optimistic that these can spur investor interest in the turnaround story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK: